SHANGHAI, Jan. 19, 2020 /PRNewswire/ -- 111, Inc.
(NASDAQ: YI) ("111" or the "Company"), a leading integrated online
and offline healthcare platform, announced the release of the sixth
episode in its 111 Insight series. The title announced today,
The Impact of Chinese Policies to Medical Industry, is
hosted by Dr. Gang Yu, Co-Founder and Executive Chairman of 111,
Inc. Dr. Yu will moderate a discussion with Dr. Xiaobin Wu, President of BeiGene Ltd, and Dr.
Darren Ji, CEO of Elpiscience
Biopharma, Ltd.
Tencent video link:
https://v.qq.com/x/page/h3052n5gvqw.html?
The Impact of Chinese Policies to Medical
Industry will feature:
- Impacts of China's healthcare
reform on the industry: driving a market switch from public
hospitals to retail channels and online channels
- Purpose of the "4+7" policy: encouraging innovative drugs and
reducing the price of patent and generic drugs
- The Internet and the online retail will play big roles to make
accessible for drugs
The 111 Insight series is produced by 111, Inc. and is hosted by
Dr. Gang Yu, Co-Founder and Executive Chairman, and Mr.
Junling Liu, Co-Founder, Chairman
and CEO. The series focuses on important topics in global health
and the state of the industry in China through interviews with industry
experts, investors, and healthcare professionals.
China's healthcare industry in
China is evolving rapidly and
there is increasing global interest in China's health reform and policies. Among the
topics that will be discussed throughout the series are: How the
Internet is reshaping China's
healthcare industry and pharmaceutical delivery market; how new
government policies and regulations impact the healthcare industry;
how new technologies are changing private health insurance; and the
opportunities and challenges facing China's aging population.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates," "target,"
"confident" and similar statements. Among other things, the
Business Outlook and quotations from management in this
announcement, as well as 111's strategic and operational plans,
contain forward-looking statements. 111 may also make written or
oral forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission, in its annual report to
shareholders, in press releases and other written materials and in
oral statements made by its officers, directors or employees to
third parties. Such statements are based upon management's current
expectations and current market and operating conditions and relate
to events that involve known or unknown risks, uncertainties and
other factors, all of which are difficult to predict and many of
which are beyond the Company's control. Forward-looking statements
involve inherent risks, uncertainties and other factors that could
cause actual results to differ materially from those contained in
any such statements. Potential risks and uncertainties include, but
are not limited to, uncertainties as to the Company's ability
comply with extensive and evolving regulatory requirements, its
ability to compete effectively in the evolving PRC general health
and wellness market, its ability to manage the growth of its
business and expansion plans, its ability to achieve or maintain
profitability in the future, its ability to control the risks
associated with its pharmaceutical retail and wholesale businesses,
and the Company's ability to meet the standards necessary to
maintain listing of its ADSs on the Nasdaq Global Market, including
its ability to cure any non-compliance with Nasdaq's continued
listing criteria. Further information regarding these and other
risks, uncertainties or factors is included in the Company's
filings with the U.S. Securities and Exchange Commission. All
information provided in this press release is as of the date of
this press release, and 111 does not undertake any obligation to
update any forward-looking statement as a result of new
information, future events or otherwise, except as required under
applicable law.
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
integrated online and offline healthcare platform in China. The Company provides hundreds of
millions of consumers with better access to pharmaceutical products
and medical services directly through its online retail pharmacy
and indirectly through its offline pharmacy network. 111 also
offers online medical services through its Internet hospital, 1
Clinic, which provides consumers with cost-effective and convenient
online consultation and electronic prescription services. In
addition to providing direct services to consumers through its
online retail pharmacy, 111 also enables offline pharmacies to
better serve their customers. The Company's online wholesale
pharmacy, 1 Drug Mall, serves as a one-stop shop for pharmacies to
source a vast selection of pharmaceutical products. The Company's
New Retail platform, by integrating the front and back ends of the
pharmaceutical supply chain, has formed a smart supply chain, which
transforms the flow of pharmaceutical products to pharmacies and
modernizes how they serve their customers.
For more information on 111, please visit
http://ir.111.com.cn/
For more information, please contact:
111, Inc.
Ms. Monica
Mu
IR Director
ir@111.com.cn
Christensen
In China
Mr. Christian Arnell
Phone: +86-10-5900-1548
E-mail: carnell@christensenir.com
In U.S.
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: lbergkamp@ChristensenIR.com
View original
content:http://www.prnewswire.com/news-releases/111-unveils-new-video-on-the-impact-of-chinese-policies-to-medical-industry-300989308.html
SOURCE 111, Inc.